I
mpact of linzagolix treatment on anemia in women with uterine fibroid related heavy menstrual bleeding: results of two
P
hase 3 clinical trials
Lead author: William Catherino, MD, PhD; Professor, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences
Key Conclusions: High and low linzagolix doses with and without ABT improved hemoglobin and ferritin levels in anemic women with uterine fibroids. In the 12-week follow-up period hemoglobin levels decreased but did not return to baseline levels.
Poster
:
Safety of linzagolix in the treatment of women with uterine fibroids: Results from two Phase 3 clinical trials
Lead author: Hugh Taylor, MD; Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine
Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
DBV Technologies S.A.: DBV Technologies to Participate in Upcoming Investor Conferences
DBV Technologies to
Upcoming Investor Conferences
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the following upcoming virtual investor conferences in May 2021.
Kempen
Life Sciences Conference, May 5, 2021
Dr. Pharis Mohideen, Chief Medical Officer, and Sebastien Robitaille, Chief Financial Officer, will participate in virtual investor meetings.
Societe
Nice Conference, May 27, 2021
Daniel Tassé, Chief Executive Officer, and Sebastien Robitaille, Chief Financial Officer, will participate in virtual investor meetings.
About DBV Technologies
DBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, DBV s method of delivering biolo
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 .
Erytech Pharma S.A.April 28, 2021 GMT
ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details
Publication of Q1 2021 results on 4 May 2021 after market close
Lyon (France) and Cambridge, MA (U.S.), April 29, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced its cash position at the end of the first quarter 2021 and that it will host its 2021 first quarter conference call and webcast on Wednesday, May 5, 2021, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.